CoChat

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium

Open access
Villaruz, Liza C., Socinski, Mark A., Abberbock, Shira, Berry, Lynne D., Johnson, Bruce E., Kwiatkowski, David J., Iafrate, A. John, Varella‐Garcia, Marileila, Franklin, Wilbur A., Camidge, D. Ross, Sequist, Lecia V., Haura, Eric B., Ladanyi, Mark, Kurland, Brenda F., Kugler, Kelly, Minna, John D., Bunn, Paul A., Kris, Mark G. · 2015 · Cancer
Cited by 125

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The advent of effective targeted therapy for BRAF V600E‐mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced‐stage BRAF‐mutant lung adenocarcinomas. METHODS: Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutation Consortium whose tumors underwent testing for mutations in epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor 2 (HER2), AKT1, BRAF, dual‐specificity mitogen‐activated protein kinase kinase 1 (MEK1), neuroblastoma RAS viral (v‐ras) oncogene homolog (NRAS), and phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit α (PIK3CA); for anaplastic lymphoma kinase (ALK) translocations; and for MET amplification. RESULTS: Twenty‐one BRAF mutations were identified in 951 patients with adenocarcinomas (2.2%; 95% confidence interval [CI], 1.4%‐3.4%): 17 (81%; 95% CI, 60%‐92%) were BRAF V600E mutations, and 4 were non‐BRAF V600E mutations. Among the 733 cases tested for all 10 genes, BRAF mutations were more likely to occur than most other genotypic abnormalities in current or former smokers (BRAF vs sensitizing EGFR, 82% vs 36%, mid‐P < .001; BRAF vs ALK, 39%, mid‐P = .003; BRAF vs other mutations, 49%, mid‐P = .02; BRAF vs patients with more than 1 oncogenic driver [doubleton], 46%, mid‐P = .04.) The double‐mutation rate was 16% among patients with BRAF mutations but 5% among patients with other genomic abnormalities (mid‐P = .045). Differences were not found in survival between patients with BRAF mutations and those with other genomic abnormalities (P > .20). CONCLUSIONS: BRAF mutations occurred in 2.2% of advanced‐stage lung adenocarcinomas, were most commonly V600E, and were associated with distinct clinicopathologic features in comparison with other genomic subtypes and with a high mutation rate in more than 1 gene. These findings underscore the importance of comprehensive genomic profiling in assessing patients with advanced lung adenocarcinomas. Cancer 2015;121:448–456. © 2014 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.29042

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Villaruz, L. C., Socinski, M. A., Abberbock, S., Berry, L. D., Johnson, B. E., Kwiatkowski, D. J., Iafrate, A. J., Varella‐Garcia, M., Franklin, W. A., Camidge, D. R., Sequist, L. V., Haura, E. B., Ladanyi, M., Kurland, B. F., Kugler, K., Minna, J. D., Bunn, P. A., & Kris, M. G.
Venue
Cancer
Publisher
Wiley
Published
2014-10
Volume
121
Issue
3
Pages
448-456
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1870303472
Cited by
125
References
7
FWCI
9.21
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.